Search

Policosanol is a valuable compound with potential applications across multiple sectors. Within the pharmaceutical field, policosanol and its main components—triacontanol, octacosanol, and hexacosanol—have shown biological activity, particularly in conditions associated with inflammation and hypercholesterolaemia. Triacontanol, specifically, serves as a plant growth promoter and is widely applied in numerous economically significant crops and microalgae, either as a pure compound or as part of policosanol extracts. This review compiles key studies addressing the bioactivity of policosanol in both plant and animal cells, enabling comparison of the different mechanisms of action. A detailed evaluation of this information opens avenues for further research. Articles were sourced from PubMed and Redalyc using specific key terms: policosanol, inflammatory mechanisms, triacontanol, cellular absorption, photosynthesis, and photoinhibition. Policosanol has been found to interfere with inflammation-related pathways, notably the NF-κB and MAPK signaling cascades. Its cholesterol-lowering capacity results from the suppression of hepatic cholesterol synthesis through the indirect inhibition of HMG-CoA reductase. Triacontanol enhances plant growth and influences biochemical and physiological traits, especially under stress, mainly by improving photosynthetic efficiency. Notably, octacosanol can suppress the activity of triacontanol in plants—a phenomenon not observed in human cells—highlighting key distinctions in how these compounds function in plant versus animal systems, which warrants further investigation.

Nerve agents are among the most potent and widely recognized chemical weapons. Recently, a new class of nerve agents, known as Novichok, has emerged as both a hazardous and frequently utilized tool in terrorist attacks. Medical professionals must gain a comprehensive understanding of the fundamental chemical and pharmacological properties of Novichok agents. This article provides a detailed review of the history, development, chemical structure, mechanism of action, toxicokinetics, and toxicology of these agents. Additionally, it discusses the latest diagnostic and treatment approaches for poisoning caused by Novichok agents. Contrary to earlier beliefs, Novichok poisoning shares similarities with other organophosphate toxins and can be effectively managed with timely and appropriate treatment. Given the global threat posed by terrorist incidents involving these agents, medical teams need to be well-versed in their characteristics to ensure optimal diagnosis and care for affected individuals.

Azithromycin (AZM), primarily recognized for its antibiotic properties, has gained attention for its ability to modulate the immune system and reduce inflammation. This review explores the impact of AZM on various immune cell types, including T cells, B cells, and natural killer (NK) cells, and its potential in treating chronic inflammatory and autoimmune conditions. AZM inhibits the mTOR signaling pathway in T cells, thereby limiting both T cell proliferation and cytokine production. It also affects B-cell function by modulating pathways such as NF-κB and CD27, thereby influencing antibody synthesis. In NK cells, AZM reduces cytotoxicity and cytokine release while preserving cell viability. The drug’s effects on immune responses, particularly on vaccination responses and reduced antibody levels, have important clinical implications. While AZM shows potential for managing conditions such as graft-versus-host disease and asthma, its varied effects highlight the need for further investigation. Further understanding of these mechanisms is crucial for optimizing AZM’s therapeutic use and minimizing unwanted immune suppression.

This review aims to explore and consolidate the therapeutic potential of colchicine, one of the oldest yet still widely used treatments. Colchicine is an alkaloid compound known for its anti-inflammatory and analgesic effects. It has been effectively used to treat conditions such as gout, familial Mediterranean fever (FMF), and Behcet’s disease. The drug’s mechanism of action involves its interaction with tubulin, a structural component of the cytoskeleton, which disrupts neutrophil functions, including adhesion, migration, and chemotaxis. Colchicine specifically inhibits tyrosine phosphorylation, a key process for neutrophil activation, and affects neutrophil deformability, preventing their extravasation. Additionally, it suppresses the production of superoxide and pro-inflammatory cytokines, such as interleukin 1β and IL-6. The drug also inhibits inflammasome activity, hindering caspase-1 activation and interleukin release. Colchicine has attracted attention during the COVID-19 pandemic due to its potential to treat severe cases and reduce mortality. It is a cost-effective and widely accessible drug with a relatively safe profile. However, its metabolism can be influenced by CYP3A4 and P-glycoprotein inhibitors, as well as by renal and hepatic impairments. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, and vomiting.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the most severe form of motor neuron degeneration. This study aims to: (1) compare genetic and non-genetic contributors to ALS development, (2) evaluate the pharmacological mechanisms of riluzole and its therapeutic potential across multiple conditions, and (3) explore treatment combinations for managing symptoms throughout ALS progression. The analysis was conducted using data from established electronic medical databases. The most frequently implicated genetic mutations in ALS include SOD1, SETX, FUS, VEGF, VAPB, ANG, TARDBP, FIG4, OPTN, ATXN2, VCP, UBQLN2, SIGMAR1, CHMP2B, PFN1, ERBB4, HNRNPA1, C9orf72, dynactin 1, H46R, and A4V. Additional risk factors include oxidative stress, glutamate-induced excitotoxicity, autoimmune responses, protein misfolding and aggregation, inflammation, and viral infections. Riluzole’s therapeutic actions are attributed to several mechanisms: (1) inhibition of repetitive neuronal firing, (2) blockade of persistent sodium currents in motor neurons, (3) enhancement of calcium-activated potassium currents, (4) reduction of presynaptic neurotransmitter release, and (5) attenuation of postsynaptic receptor responses. Combining riluzole with antioxidants such as vitamins E and C, coenzyme Q10, creatine, and selenium may enhance therapeutic efficacy in ALS. Symptomatic treatments include nonsteroidal anti-inflammatory drugs, opioids for pain relief, and agents like Baclofen and Dantrolene to manage spasticity. Memantine, Nimesulide, and Gabapentin show promise for further research. Due to its diverse mechanisms, riluzole is also being investigated for use in Parkinson’s disease, Huntington’s disease, Machado-Joseph disease, multiple sclerosis, spinal muscular atrophy, and various neuropsychiatric conditions, including anxiety, autism, depression, and schizophrenia.